These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30742306)

  • 1. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
    Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
    Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy.
    Li X; Sabbatini D; Pegoraro E; Bello L; Clemens P; Guglieri M; van den Anker J; Damsker J; McCall J; Dang UJ; Hoffman EP; Jusko WJ
    J Clin Pharmacol; 2024 Sep; 64(9):1130-1140. PubMed ID: 38682893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
    Grounds MD; Lloyd EM
    J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
    Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
    Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
    Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
    Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
    Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
    Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
    Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP
    Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vamorolone: First Approval.
    Keam SJ
    Drugs; 2024 Jan; 84(1):111-117. PubMed ID: 38103149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of different doses of vamorolone in boys with Duchenne muscular dystrophy: a systematic review and network meta-analysis.
    Wang Q; Zeng Y; Jiao L; He J; Li B; Guo Y; Song Z
    Front Neurol; 2024; 15():1456559. PubMed ID: 39233679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
    Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
    Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.
    Fiorillo AA; Tully CB; Damsker JM; Nagaraju K; Hoffman EP; Heier CR
    Physiol Genomics; 2018 Sep; 50(9):735-745. PubMed ID: 29883261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.
    Fang Y; McDonald CM; Clemens PR; Gordish HD; Illei K; Hoffman EP; ; Dang UJ
    J Neuromuscul Dis; 2023; 10(3):349-364. PubMed ID: 36806514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial.
    Ahmet A; Tobin R; Dang UJ; Rooman R; Guglieri M; Clemens PR; Hoffman EP; Ward LM
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39097643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.
    Liu X; Wang Y; Gutierrez JS; Damsker JM; Nagaraju K; Hoffman EP; Ortlund EA
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24285-24293. PubMed ID: 32917814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.
    Previtali SC; Gidaro T; Díaz-Manera J; Zambon A; Carnesecchi S; Roux-Lombard P; Spitali P; Signorelli M; Szigyarto CA; Johansson C; Gray J; Labolle D; Porte Thomé F; Pitchforth J; Domingos J; Muntoni F
    Pharmacol Res; 2020 Sep; 159():104999. PubMed ID: 32535224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.
    Dang UJ; Ziemba M; Clemens PR; Hathout Y; Conklin LS; ; Hoffman EP
    Hum Mol Genet; 2020 Aug; 29(15):2481-2495. PubMed ID: 32592467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.